Guardant Health
Cancer Research UK, Guardant Health Ink Research, Data Sharing Partnership
The collaboration aims to help accelerate the discovery and development of cancer drugs and diagnostics through ongoing and potentially new clinical trials.
Top Five Articles on GenomeWeb Last Week: Guardant Health $83.4M Lawsuit Verdict, More
Last week, GenomeWeb's readers were most interested in news that Guardant Health is liable for $83.4 million in damages in an intellectual property legal battle with TwinStrand Biosciences.
Jury Levies $83.4M Verdict Against Guardant Health in TwinStrand Biosciences Patent Lawsuit
Guardant said that it plans to appeal the decision made by a jury in the US District Court for the District of Delaware.
Guardant Health Q3 Revenues Rise 22 Percent as Oncology Test Volume Continues to Grow
The company is celebrating recent milestones for its MRD testing arm and its anticipated expansion into colorectal cancer screening.
Guardant Health, Flatiron Health Forge Genomic Profiling Test Deal
The firms will integrate Guardant's genomic profiling tests for early- and advanced-stage cancers into Flatiron's cloud-based electronic medical record tool.